3 recruiting, 2 not yet recruiting, 1 active not recruiting, 1 terminated. 5 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Head and Neck Squamous Cell Carcinomas: new trials by email Literature Review of Head and Neck Squamous Cell Carcinomas trials Research Report on Head and Neck Squamous Cell Carcinomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors BL-M08D1 - Head and Neck Squamous Cell Carcinomas, Solid Tumors | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 30 | 2026-09-01 | 2026-08-27 |
| A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors BL-B16D1 - Head and Neck Squamous Cell Carcinomas, Solid Tumor | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 21 | 2024-06-27 | 2025-09-18 |
| Myeloprotection With Trilaciclib in Pan-cancer Population Trilaciclib Injection, Paclitaxel, Carboplatin - Non-Small Cell Lung Cancer, Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 132 | 2024-03-01 | 2024-03-07 |
| Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant) - Head and Neck Squamous Cell Carcinomas | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 24 | 2023-02-05 | 2024-09-19 |
| Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma Tislelizumab, Nab-paclitaxel, Carboplatin - Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma | Phase 2 | Unknown | Xiang Lu | 30 | 2023-01-01 | 2024-02-01 |
| Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) Tislelizumab（neoadjuvant）, Cisplatin （neoadjuvant）, Nab-paclitaxel （neoadjuvant） - Head and Neck Squamous Cell Carcinomas | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 537 | 2022-10-28 | 2024-05-17 |
| PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors PF-07265028, Sasanlimab - Advanced Solid Tumors, Gastric Cancer | Phase 1 | Terminated | Pfizer | 21 | 2022-02-24 | 2026-02-19 |
| A Study of Toripalimab as Consolidation Therapy After Postoperative Chemoradiotherapy in HNSCC Consolidation Toripalimab - Head and Neck Squamous Cell Carcinomas | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 41 | 2021-06-22 | 2023-04-14 |
Squamous Cell Carcinoma of Head and Neck (8) · Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1) · Uterine Cervical Neoplasms (1)
Carcinoma (8) · Carcinoma, Squamous Cell (8) · Head and Neck Neoplasms (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms by Site (8) · Neoplasms, Glandular and Epithelial (8) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Breast Diseases (1) · Digestive System Diseases (1)
Carboplatin (3) · Adjuvants, Pharmaceutic (2) · Neoadjuvant Therapy (2) · tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Dasatinib (1) · Paclitaxel (1) · Quercetin (1) · Radiation (1) · Surgical Procedures, Operative (1) · trilaciclib (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Pfizer (1) · Sun Yat-sen University (1) · Xiang Lu (1)
China (7) · Japan (1) · United States (1)
Guangyuan Hu, professor (1) · Song Fan, Doctor (1) · Ye Guo (1)